Featured Research

from universities, journals, and other organizations

Limited Course of Thalidomide Effective in Treating AIDS-Related Mouth Ulcers

Date:
May 22, 1997
Source:
National Institute of Allergy and Infectious Diseases
Summary:
Thalidomide effectively heals severe mouth and throat ulcers in people with HIV infection, according to a study supported by the National Institute of Allergy and Infectious Diseases (NIAID).

Thalidomide effectively heals severe mouth and throat ulcers in people with HIV infection, according to a study supported by the National Institute of Allergy and Infectious Diseases (NIAID) and reported in the May 22, 1997, issue of The New England Journal of Medicine.

"For the many patients with HIV infection who suffer from these ulcers, eating can be excruciatingly painful, which exacerbates wasting and debilitation," says Division of AIDS Director Jack Killen, M.D. "Thalidomide is the first treatment shown in a scientific study to heal these ulcers, but the course should be carefully monitored and limited in its duration because of the drug's potential toxicity."

The ulcers of 55 percent of the patients receiving four weeks of thalidomide healed completely, compared to healing in only 7 percent of the patients receiving placebo. Almost all (90 percent) of those receiving thalidomide had at least partial healing.

The AIDS Clinical Trials Group (ACTG), a network of clinical trial sites supported by NIAID, conducted this study, called ACTG 251. Baseline and weekly health evaluations of study volunteers included a quality-of-life questionnaire to assess pain and discomfort during eating. Results from these questionnaires showed that the thalidomide group improved much more than the placebo group in regaining comfort while eating.

"Thalidomide appears to have great potential as a therapy for HIV-infected patients who have severe oral aphthous ulcers," says Lawrence Fox, M.D., Ph.D., one of two NIAID authors, "but only when administered by a physician who is vigilant for the possible serious side effects, including irreversible, painful peripheral nerve damage, rash and birth defects.

Patients experienced only minimal adverse effects while they were taking thalidomide. Seven patients reported drowsiness and seven had rashes. The authors caution, however, that those patients who received thalidomide showed a small, but statistically significant increase in HIV ribonucleic acid (RNA) blood levels from the baseline through the fourth week of the study as compared to patients receiving placebo. "There is not sufficient information, however, to judge whether this increase is of any clinical significance," says study director Jeffrey M. Jacobson, M.D., of the Departments of Medicine at both Bronx Veterans' Affairs Medical Center and Mount Sinai School of Medicine, New York.

A second reason for caution, according to the study results, is that patients taking thalidomide had elevated plasma levels of tumor necrosis factor (TNF)-alpha, a substance released from phagocytes and from some T cells during the immune response and known to provoke HIV replication and expression from infected cells. This was unanticipated because earlier studies had reported that thalidomide inhibited production of TNF-alpha . These patients also showed increased soluble TNF-alpha receptor levels, a phenomenon shown to be associated with clinical progression of HIV disease.

Scientists at 19 sites conducted the double-blind, randomized, placebo-controlled study. Of 57 volunteers, 29 received thalidomide. The remaining patients received placebo, but were offered open-label thalidomide at the endpoint of the study. All patients in the study were HIV-positive and had oral or throat ulcers for at least two weeks before the start of the study.

At each of the study sites, physicians evaluated patients in initial screenings, in baseline physical examinations, and then weekly throughout the study. Because of thalidomide's well-known ability to cause severe birth defects, every precaution was taken to prevent pregnancy, and pregnancy tests were given weekly to women of childbearing age. Each baseline and weekly evaluation included an assessment of nerve function, (peripheral sensory nerve disorders are a known complication of longer-term thalidomide treatment), laboratory analyses of blood cells, serum chemistries and serum thalidomide levels, and evaluation of liver and kidney function. The National Center for Research Resources supported this study in part through the General Clinical Research Center Units. Andrulis Pharmaceutical Corporation of Beltsville, Md., provided thalidomide and placebo for the study.

In addition to Drs. Jacobson and Fox, authors are John S. Greenspan, B.Sc., B.D.S., Ph.D., and Laurie A. MacPhail, D.M.D., Ph.D., both of the Department of Stomatology, University of California, San Francisco; John Spritzler, Sc.D., and Miriam Chernoff, Ph.D., both from the Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Mass.; Nzeera Ketter, M.D., Division of AIDS, NIAID, Bethesda, Md.; John L. Fahey, M.D., Department of Medicine, University of California, Los Angeles; J. Brooks Jackson, M.D., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Md.; Albert W. Wu, M.D., M.P.H., Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.; Guillermo J. Vasquez, M.D., Department of Medicine, University of Puerto Rico Medical School, San Juan; and David A. Wohl, M.D., Department of Medicine, University of North Carolina, Chapel Hill.

Other participating study sites are Mount Sinai Medical Center, New York; University of Hawaii, Manoa; University of Southern California, Los Angeles; Northwestern University, Chicago; University of Washington, Seattle; Stanford University, Palo Alto, Calif.; Harvard Medical School, Boston, Mass.; New York University, New York; Indiana University, Indianapolis; Meharry Medical College, Nashville, Tenn.; University of Pennsylvania, Philadelphia; Case Western Reserve University, Cleveland, Ohio; University of Colorado Health Sciences Center, Denver; University of Rochester, New York; and Albert Einstein College of Medicine, New York.

NIAID, a component of the National Institutes of Health (NIH), conducts and supports research aimed at preventing, diagnosing and treating illnesses such as AIDS and other sexually transmitted diseases, tuberculosis, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services. ### References: Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey J, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New Engl J Med 1997;336:1487-93.

Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.

Peterson PK, Hu S, Sheng WS, et al. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995;172:1137-40.

Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.

Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.

Sampaio EP, Sarno EN, Galilly R, Cohn ZA, kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.

Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.

Wulff CH, Hover H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985;112:475-80.

NIAID press releases, fact sheets and other materials are available on the Internet via the NIAID home page at http://www.niaid.nih.gov.


Story Source:

The above story is based on materials provided by National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute of Allergy and Infectious Diseases. "Limited Course of Thalidomide Effective in Treating AIDS-Related Mouth Ulcers." ScienceDaily. ScienceDaily, 22 May 1997. <www.sciencedaily.com/releases/1997/05/970522074044.htm>.
National Institute of Allergy and Infectious Diseases. (1997, May 22). Limited Course of Thalidomide Effective in Treating AIDS-Related Mouth Ulcers. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/1997/05/970522074044.htm
National Institute of Allergy and Infectious Diseases. "Limited Course of Thalidomide Effective in Treating AIDS-Related Mouth Ulcers." ScienceDaily. www.sciencedaily.com/releases/1997/05/970522074044.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins